21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
19:42 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Follow-on roundup: Ultragenyx, Adamas, Rocket

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $250 million on Jan. 23 through the sale of 4.4 million shares at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Goldman Sachs...
22:56 , Jan 24, 2018 |  BC Extra  |  Financial News

Follow-on roundup

At least six companies priced follow-ons, raising more than $600 million total. Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $250 million on Tuesday through the sale of 4.4 million shares at $57 in a...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
23:10 , Aug 28, 2017 |  BC Week In Review  |  Clinical News

FDA approves Adamas' Gocovri for PD dyskinesia

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) said FDA approved Gocovri amantadine to treat dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Adamas said Gocovri is the first FDA-approved drug for...
22:25 , Aug 24, 2017 |  BC Extra  |  Company News

FDA approves Adamas' Gocovri for PD dyskinesia

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) gained $5.37 (38%) to $19.60 in after-hours trading Thursday after it said FDA approved Gocovri amantadine (formerly ADS-5102) to treat dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
23:47 , Jul 5, 2017 |  BC Extra  |  Company News

Management tracks

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....
18:49 , May 12, 2017 |  BC Week In Review  |  Company News

Adamas, HCR in $100M royalty deal

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) will receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners (Stamford, Conn.). The company is to receive $35 million up front and $65...
23:13 , May 11, 2017 |  BC Extra  |  Financial News

Adamas, HCR in $100M royalty deal

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) is to receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners. The company is to receive $35 million up front and $65 million...